What is the price target for INAB stock?
10 analysts have analysed INAB and the average price target is 6.46 USD. This implies a price increase of 345.52% is expected in the next year compared to the current price of 1.45.
NASDAQ:INAB • US45674E2081
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IN8BIO INC (INAB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Jones Trading | Upgrade | Hold -> Buy |
| 2024-11-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-12 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-06-14 | Jones Trading | Maintains | Buy -> Buy |
| 2024-06-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-18 | Laidlaw & Co. | Initiate | Buy |
| 2024-03-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-13 | JonesTrading | Initiate | Buy |
| 2023-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-05 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-24 | Mizuho | Reiterate | Buy |
| 2023-04-17 | EF Hutton | Maintains | Buy |
| 2023-03-31 | EF Hutton | Reiterate | Buy |
| 2023-03-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-29 | EF Hutton | Initiate | Buy |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 1,375.98% | N/A 83.65% | N/A 87.92% | N/A 57.86% | N/A 26.33% | N/A 37.18% | |||||||||
| EBITDA YoY % growth | -1.9M | -4.96M -161.05% | -8.47M -70.77% | -14.02M -65.53% | -27.91M -99.07% | -28.504M -2.13% | -27.764M 2.60% | -18.09M 34.84% | N/A -46.60% | N/A -80.77% | N/A 29.79% | N/A -15.15% | N/A 76.32% | N/A 288.89% | N/A 141.18% | N/A | |
| EBIT YoY % growth | -2M | -5.06M -153.00% | -8.56M -69.17% | -14.65M -71.14% | -28.52M -94.68% | -30.337M -6.37% | -29.599M 2.43% | -19.861M 32.90% | N/A -3.90% | N/A -20.33% | N/A 19.57% | N/A -31.25% | N/A 75.61% | N/A 343.76% | N/A 98.00% | N/A 36.88% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -42.60 10.76% | -30.30 28.87% | -17.40 42.57% | -4.64 73.33% | N/A 62.19% | N/A -12.79% | N/A 240.89% | N/A -158.72% | N/A 58.57% | N/A 132.33% | N/A 246.51% | N/A 86.58% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.70 66.49% | -0.74 39.95% | -0.67 21.40% | -0.70 -56.40% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.26M 7.06% | -5.469M -5.16% | -5.833M -47.05% | -6.238M -23.95% |
All data in USD
10 analysts have analysed INAB and the average price target is 6.46 USD. This implies a price increase of 345.52% is expected in the next year compared to the current price of 1.45.
IN8BIO INC (INAB) will report earnings on 2026-05-01.
The consensus EPS estimate for the next earnings of IN8BIO INC (INAB) is -0.7 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering IN8BIO INC (INAB) is 10.